Benjamin F. Edwards & Company’s Charles River Laboratories CRL Stock Holding History

Benjamin F. Edwards & Company’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$154K	Buy	745 +50	+7%	+$11.3K	﹤0.01%	981
2024 Q1	$188K	Sell	695 -62	-8%	-$14.8K	﹤0.01%	926
2023 Q4	$179K	Buy	757 +625	+473%	+$123K	﹤0.01%	904
2023 Q3	$26K	Buy	132 +66	+100%	+$13.6K	﹤0.01%	1196
2023 Q2	$14K	Hold	66	–	–	﹤0.01%	1348
2023 Q1	$13K	Sell	66 -1	-1%	-$227	﹤0.01%	1352
2022 Q4	$15K	Buy	67 +41	+158%	+$8.95K	﹤0.01%	1336
2022 Q3	$5K	Buy	+26	New	+$5.61K	﹤0.01%	1542
2021 Q2	–	Sell	-60	Closed	-$17K	–	1693
2021 Q1	$17K	Buy	+60	New	+$16.7K	﹤0.01%	1237
2019 Q3	–	Sell	-100	Closed	-$14K	–	1848
2019 Q2	$14K	Hold	100	–	–	﹤0.01%	1304
2019 Q1	$15K	Buy	+100	New	+$13.1K	﹤0.01%	1208

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.4B AUM 49.36% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Benjamin F. Edwards & Company's CRL Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its Charles River Laboratories (CRL) stake by 7.2% in Q2 2024, buying an estimated $11.3K and bringing the position to 745 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #981.

Benjamin F. Edwards & Company first reported a position in CRL in Q1 2019 and has held it in 11 quarters since. The position peaked at $188K in Q1 2024. 665 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

Benjamin F. Edwards & Company held 745 shares of Charles River Laboratories worth $154K as of Q2 2024.
Benjamin F. Edwards & Company bought 50 Charles River Laboratories shares in Q2 2024, an estimated $11.3K.
Charles River Laboratories made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #981 holding.
Benjamin F. Edwards & Company first reported a position in Charles River Laboratories in Q1 2019 and has held it in 11 quarters since.
Benjamin F. Edwards & Company's Charles River Laboratories position peaked at $188K in Q1 2024.
665 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.